Freeman Technology appoints operations manager

Jamie Clayton takes responsibility for day-to-day activities

Powder characterisation company Freeman Technology has appointed Jamie Clayton to the new post of operations manager, to be based at the company’s UK headquarters in Welland, Worcestershire.

Clayton has been with Freeman Technology since 2008 in a role that has encompassed both sales and applications support. As operations manager he will be responsible for all the day-to-day activities of the company, including overall management of the administration, production, r&d, sales and customer support teams.

In expanding the management team Tim Freeman, director of operations, anticipates further growth and greater opportunity to contribute expertise to the powder processing industries.

‘We want to deliver the best possible technical and applications support to our customers at all times and part of Jamie’s new role will be to ensure that every aspect of our operation runs efficiently,’ he said.

You may also like

Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Manufacturing

Sovereign demonstrates turnkey bottle labelling solution at PPMA Total Show 2025

Integrated labelling and tamper-proofing technologies showcased for high-speed production lines
Manufacturing

Vapourtec unveils compact benchtop peptide synthesiser

Peptide-Builder uses VBFR technology to improve efficiency and reduce waste
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Pharma outsourcing trends 2025: partnership, precision and resilience

The Bachem team shares its insights on the evolving relationship between pharma companies and CDMOs
Manufacturing

When the chemistry is right: Vetter expands capacities with a pure water generator from Pharmatec

The production of injectable active pharmaceutical ingredients (APIs) is a highly complex process that leaves no room for error
Regulatory

Roca secures EMA recognition of radiation maculopathy as a distinct indication and Orphan Drug Designation

Roca Therapeutics (Roca) announces the granting of Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its lead clinical candidate, RCT002, to treat radiation maculopathy
Manufacturing

Complete security with the REACTEX range of lids and lid accessories

The mechanical seal is suitable for use with 10 mm shafts of any material with product contacting parts of borosilicate glass 3.3, FFKM and PTFE
Subscribe now